Duran, A. O. Et Al. 2014. XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.23 , 10375-10379.

Duran, A. O., Karaca, H., Besiroglu, M., Bayoglu, I. V., Menekse, S., Yapici, H. S., ... Yazilitas, D.(2014). XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.23, 10375-10379.

Duran, Ayse Et Al. "XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology," ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.23, 10375-10379, 2014

Duran, Ayse O. Et Al. "XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology." ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.23, pp.10375-10379, 2014

Duran, A. O. Et Al. (2014) . "XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology." ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.23, pp.10375-10379.

@article{article, author={Ayse Ocak Duran Et Al. }, title={XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology}, journal={ASIAN PACIFIC JOURNAL OF CANCER PREVENTION}, year=2014, pages={10375-10379} }